MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis
NASDAQ:MEDP • US58506Q1094
447.09 USD
+9.01 (+2.06%)
At close: Feb 26, 2026
447.09 USD
0 (0%)
After Hours: 2/26/2026, 8:00:00 PM
We assign a fundamental rating of 7 out of 10 to MEDP. MEDP was compared to 58 industry peers in the Life Sciences Tools & Services industry. MEDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDP is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, MEDP could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year MEDP was profitable.
- In the past year MEDP had a positive cash flow from operations.
- Each year in the past 5 years MEDP has been profitable.
- Each year in the past 5 years MEDP had a positive operating cash flow.
1.2 Ratios
- MEDP has a Return On Assets of 22.84%. This is amongst the best in the industry. MEDP outperforms 98.28% of its industry peers.
- The Return On Equity of MEDP (98.27%) is better than 100.00% of its industry peers.
- With an excellent Return On Invested Capital value of 71.19%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- MEDP had an Average Return On Invested Capital over the past 3 years of 49.20%. This is significantly above the industry average of 11.97%.
- The 3 year average ROIC (49.20%) for MEDP is below the current ROIC(71.19%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.84% | ||
| ROE | 98.27% | ||
| ROIC | 71.19% |
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
1.3 Margins
- MEDP has a Profit Margin of 17.83%. This is amongst the best in the industry. MEDP outperforms 89.66% of its industry peers.
- MEDP's Profit Margin has improved in the last couple of years.
- MEDP has a better Operating Margin (21.14%) than 89.66% of its industry peers.
- MEDP's Operating Margin has improved in the last couple of years.
- With a Gross Margin value of 30.06%, MEDP is not doing good in the industry: 74.14% of the companies in the same industry are doing better.
- MEDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.14% | ||
| PM (TTM) | 17.83% | ||
| GM | 30.06% |
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
2. Health
2.1 Basic Checks
- MEDP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
- MEDP has less shares outstanding than it did 5 years ago.
- MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- MEDP has an Altman-Z score of 6.62. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
- MEDP has a better Altman-Z score (6.62) than 91.38% of its industry peers.
- MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.62 |
ROIC/WACC6.58
WACC10.82%
2.3 Liquidity
- A Current Ratio of 0.74 indicates that MEDP may have some problems paying its short term obligations.
- Looking at the Current ratio, with a value of 0.74, MEDP is doing worse than 93.10% of the companies in the same industry.
- MEDP has a Quick Ratio of 0.74. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.74, MEDP is not doing good in the industry: 91.38% of the companies in the same industry are doing better.
- MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
- MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.14%, which is quite impressive.
- Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 31.30% on average per year.
- The Revenue has grown by 19.97% in the past year. This is quite good.
- Measured over the past years, MEDP shows a very strong growth in Revenue. The Revenue has been growing by 22.27% on average per year.
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%
3.2 Future
- The Earnings Per Share is expected to grow by 10.29% on average over the next years. This is quite good.
- Based on estimates for the next years, MEDP will show a quite strong growth in Revenue. The Revenue will grow by 10.47% on average per year.
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue Next Year11.71%
Revenue Next 2Y9.56%
Revenue Next 3Y9.5%
Revenue Next 5Y10.47%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 29.22 indicates a quite expensive valuation of MEDP.
- Compared to the rest of the industry, the Price/Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 63.79% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.11, MEDP is valued at the same level.
- Based on the Price/Forward Earnings ratio of 26.60, the valuation of MEDP can be described as expensive.
- MEDP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MEDP is cheaper than 65.52% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.13. MEDP is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.22 | ||
| Fwd PE | 26.6 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MEDP is valued a bit cheaper than 65.52% of the companies in the same industry.
- MEDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MEDP is cheaper than 87.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.47 | ||
| EV/EBITDA | 21.49 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of MEDP may justify a higher PE ratio.
PEG (NY)2.96
PEG (5Y)0.93
EPS Next 2Y10.52%
EPS Next 3Y10.19%
5. Dividend
5.1 Amount
- MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
447.09
+9.01 (+2.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-09 2026-02-09/amc
Earnings (Next)04-20 2026-04-20/amc
Inst Owners87.1%
Inst Owner Change-2.86%
Ins Owners0.44%
Ins Owner Change-5.64%
Market Cap12.59B
Revenue(TTM)2.53B
Net Income(TTM)451.12M
Analysts52.22
Price Target557.47 (24.69%)
Short Float %5.92%
Short Ratio4.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.54%
Min EPS beat(2)7.52%
Max EPS beat(2)9.56%
EPS beat(4)4
Avg EPS beat(4)9.37%
Min EPS beat(4)2.57%
Max EPS beat(4)17.84%
EPS beat(8)8
Avg EPS beat(8)12.36%
EPS beat(12)11
Avg EPS beat(12)11.35%
EPS beat(16)15
Avg EPS beat(16)14.34%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.75%
Max Revenue beat(2)0.93%
Revenue beat(4)4
Avg Revenue beat(4)3.88%
Min Revenue beat(4)0.75%
Max Revenue beat(4)9.78%
Revenue beat(8)4
Avg Revenue beat(8)0.78%
Revenue beat(12)7
Avg Revenue beat(12)1.31%
Revenue beat(16)10
Avg Revenue beat(16)1.28%
PT rev (1m)0.63%
PT rev (3m)7.24%
EPS NQ rev (1m)1.2%
EPS NQ rev (3m)1.83%
EPS NY rev (1m)0%
EPS NY rev (3m)0.52%
Revenue NQ rev (1m)2.48%
Revenue NQ rev (3m)2.49%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.22 | ||
| Fwd PE | 26.6 | ||
| P/S | 4.98 | ||
| P/FCF | 18.47 | ||
| P/OCF | 17.66 | ||
| P/B | 27.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 21.49 |
EPS(TTM)15.3
EY3.42%
EPS(NY)16.81
Fwd EY3.76%
FCF(TTM)24.21
FCFY5.41%
OCF(TTM)25.32
OCFY5.66%
SpS89.82
BVpS16.3
TBVpS-8.4
PEG (NY)2.96
PEG (5Y)0.93
Graham Number74.9
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.84% | ||
| ROE | 98.27% | ||
| ROCE | 84.68% | ||
| ROIC | 71.19% | ||
| ROICexc | 333.94% | ||
| ROICexgc | N/A | ||
| OM | 21.14% | ||
| PM (TTM) | 17.83% | ||
| GM | 30.06% | ||
| FCFM | 26.95% |
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
ROICexc(3y)169.04%
ROICexc(5y)114.84%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)58.52%
ROCE(5y)48.87%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y101.11%
ROICexc growth 5Y74.12%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
F-Score7
Asset Turnover1.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.49% | ||
| Cap/Sales | 1.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 126.67% | ||
| Profit Quality | 151.15% | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 6.62 |
F-Score7
WACC10.82%
ROIC/WACC6.58
Cap/Depr(3y)125.21%
Cap/Depr(5y)134.9%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.98%
Profit Quality(3y)144.35%
Profit Quality(5y)141.17%
High Growth Momentum
Growth
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%
Revenue Next Year11.71%
Revenue Next 2Y9.56%
Revenue Next 3Y9.5%
Revenue Next 5Y10.47%
EBIT growth 1Y19.71%
EBIT growth 3Y24.28%
EBIT growth 5Y26.22%
EBIT Next Year13.88%
EBIT Next 3Y12.83%
EBIT Next 5Y12.46%
FCF growth 1Y19.15%
FCF growth 3Y24.75%
FCF growth 5Y24.56%
OCF growth 1Y17.15%
OCF growth 3Y22.49%
OCF growth 5Y22.49%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
Can you provide the valuation status for MEDPACE HOLDINGS INC?
ChartMill assigns a valuation rating of 5 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
What is the profitability of MEDP stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?
The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 29.22 and the Price/Book (PB) ratio is 27.43.
How financially healthy is MEDPACE HOLDINGS INC?
The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.